NEW YORK — Triumvira Immunologics on Thursday completed an extension of a Series A financing round, having raised approximately $100 million total in the round.
The extension included new and existing investors, with significant participation from the new investor B Capital Group. Other new investors include ATEM Capital and the Myeloma Investment Fund, while existing investors like Leaps By Bayer and Northpond Ventures also participated.
Austin, Texas-based Triumvira will use the funding for further preclinical and clinical development of its T-cell antigen coupler (TAC)-T cell therapy programs. The company says its TAC receptors interact with natural T-cell receptors to help the cells recognize and eliminate tumor cells in a manner that differs from CAR-T and engineered T-cell receptor therapies.
In September 2021, Triumvira announced the first patient was dosed in its Phase I/II trial of its HER2-targeted autologous T-cell therapy, or TAC01-HER2. The TACTIC-2 trial is investigating the safety, tolerability, and efficacy of the treatment in about 70 patients with HER2-positive metastatic, advanced, unresectable breast, gastric, and other solid tumors.